Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07GHA
|
|||
| Drug Name |
PLX2853
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60; ICD-9: 205] | Phase 1/2 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1/2 | [1] | ||
| Company |
Plexxikon
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bromodomain-containing protein 4 (BRD4) | Target Info | Inhibitor | [2] |
| WikiPathways | Chemical Compounds to monitor Proteins | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04493619) PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.